Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial

Jones, J. D., Rajachandran, L., Yocca, F., Risinger, R., De Vivo, M., Sabados, J., Levin, F. R., & Comer, S. D. (2023). Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial. The American Journal of Drug and Alcohol Abuse, 49(1), 109–122. https://doi.org/10.1080/00952990.2022.2144743
Authors:
Jermaine D Jones
Lavanya Rajachandran
Frank Yocca
Robert Risinger
Michael De Vivo
Jeff Sabados
Frances R Levin
Sandra D Comer
Affiliated Authors:
Jermaine D Jones
Frances R Levin
Sandra D Comer
Columbia Affiliation:
Subjects:
Dexmedetomidine (MeSH)
Opioid-Related Disorders (MeSH)
Substance Withdrawal Syndrome (MeSH)
Author Keywords:
opioid withdrawal
dexmedetomidine
medications development
opioid use disorder
opioid dependence
elink
Publication Type:
Article
Unique ID:
10.1080/00952990.2022.2144743
PMID:
36630319
DOI:
10.1080/00952990.2022.2144743
Journal:
American Journal of Drug and Alcohol Abuse
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record

Record Created: